Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume -, Issue -, Pages 135245851879406
Publisher
SAGE Publications
Online
2018-08-24
DOI
10.1177/1352458518794063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review
- (2018) Christopher J. Weir et al. BMC Medical Research Methodology
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Primary and secondary progressive MS have a similar age at onset of progression – YES
- (2017) Sandra Vukusic Multiple Sclerosis Journal
- Primary and secondary progressive MS have a similar age at onset of progression – NO
- (2017) Helen Tremlett et al. Multiple Sclerosis Journal
- Primary and secondary progressive MS have a similar age at onset of progression – Commentary
- (2017) Marcus Koch Multiple Sclerosis Journal
- Advancing trial design in progressive multiple sclerosis
- (2017) David H Miller et al. Multiple Sclerosis Journal
- Progressive MS trials: Lessons learned
- (2017) Carmen Tur et al. Multiple Sclerosis Journal
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary and secondary progressive MS have a similar age at onset of progression – YES
- (2017) Sandra Vukusic Multiple Sclerosis Journal
- Primary and secondary progressive MS have a similar age at onset of progression – NO
- (2017) Helen Tremlett et al. Multiple Sclerosis Journal
- Primary and secondary progressive MS have a similar age at onset of progression – Commentary
- (2017) Marcus Koch Multiple Sclerosis Journal
- Advancing trial design in progressive multiple sclerosis
- (2017) David H Miller et al. Multiple Sclerosis Journal
- Progressive MS trials: Lessons learned
- (2017) Carmen Tur et al. Multiple Sclerosis Journal
- Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US
- (2016) E. Jones et al. BMC HEALTH SERVICES RESEARCH
- A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
- (2016) Helga Westerlind et al. Multiple Sclerosis Journal
- Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note
- (2016) Guoqiao Wang et al. Multiple Sclerosis Journal
- A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
- (2016) Helga Westerlind et al. Multiple Sclerosis Journal
- Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note
- (2016) Guoqiao Wang et al. Multiple Sclerosis Journal
- Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
- (2015) Daniel Ontaneda et al. LANCET NEUROLOGY
- Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression
- (2015) Christian Röver et al. PLoS One
- Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
- (2014) Jeremy Chataway et al. LANCET
- Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression
- (2013) Simon M Steinvorth et al. Multiple Sclerosis Journal
- Treatment trials in progressive MS—current challenges and future directions
- (2013) Marcus W. Koch et al. Nature Reviews Neurology
- The cost burden of multiple sclerosis in the United States: a systematic review of the literature
- (2013) Gabriel Adelman et al. JOURNAL OF MEDICAL ECONOMICS
- The quality of reports of randomized trials in multiple sclerosis: a review
- (2012) Alessio Signori et al. Multiple Sclerosis Journal
- Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data
- (2012) Jan-Patrick Stellmann et al. PLoS One
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- The economic cost of brain disorders in Europe
- (2011) J. Olesen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design
- (2011) Richard Nicholas et al. Multiple Sclerosis Journal
- Evidence for a two-stage disability progression in multiple sclerosis
- (2010) E. Leray et al. BRAIN
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability
- (2010) Antonio Scalfari et al. BRAIN
- The natural history of secondary progressive multiple sclerosis
- (2010) M. Koch et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Assessing changes in relapse rates in multiple sclerosis
- (2010) Seidu Inusah et al. Multiple Sclerosis Journal
- A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
- (2010) Jeremy Chataway et al. Multiple Sclerosis Journal
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started